Last reviewed · How we verify
EBR/GZR
EBR/GZR is a fixed-dose combination of elbasvir and grazoprevir that inhibits hepatitis C virus NS5A and NS3/4A proteases to block viral replication.
EBR/GZR is a fixed-dose combination of elbasvir and grazoprevir that inhibits hepatitis C virus NS5A and NS3/4A proteases to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6).
At a glance
| Generic name | EBR/GZR |
|---|---|
| Also known as | Zepatier |
| Sponsor | Dallas VA Medical Center |
| Drug class | Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor) |
| Target | Hepatitis C virus NS5A protein and NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Elbasvir is an NS5A inhibitor that disrupts hepatitis C virus replication and assembly, while grazoprevir is an NS3/4A protease inhibitor that prevents viral polyprotein processing. Together, they provide direct-acting antiviral activity against hepatitis C virus across multiple genotypes with a high barrier to resistance.
Approved indications
- Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6)
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) (PHASE2)
- Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (PHASE3)
- Study of Oral Treatments for Hepatitis C (PHASE4)
- An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) (PHASE3)
- Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) (PHASE4)
- EBR/GZR for HCV-1b Patients Receiving Hemodialysis (PHASE4)
- Impact of Hepatitis C Therapy and Bone Health (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EBR/GZR CI brief — competitive landscape report
- EBR/GZR updates RSS · CI watch RSS
- Dallas VA Medical Center portfolio CI